K-Beauty Stocks: The Complete Guide for Global Investors (2026)

For roughly 80 years, one name sat at the top of Korean cosmetics: Amorepacific, the house behind Sulwhasoo and Laneige. Then, in August 2025, an 11-year-old company most Western investors had never heard of quietly passed it. APR — maker of the Medicube LED face masks flooding TikTok — is now worth ₩12.5 trillion, about 1.8× Amorepacific (as of July 28, 2026). That single overtaking tells you almost everything about where K-beauty as an investment is heading.

🧭 What Are “Korean Beauty Stocks” — and What This Guide Is Not

Korean beauty stocks are the shares of cosmetics companies listed in Korea and traded in won on the Korea Exchange (KRX) — the brands, manufacturers and device makers behind the K-beauty export boom. That is a deliberately narrow definition, and it is what makes this guide different from almost everything else you will find on the topic.

Search “K-beauty stocks” and you mostly get two things that are not this:

• US-listed cosmetics stocks — e.l.f. Beauty, Estée Lauder, or the retailer MINISO. These sell K-beauty-adjacent products but are American or Chinese equities. They are not how you get exposure to the Korean export champions.
• Shopping and startup guides — “best K-beauty brands to buy” (the products) or “how to launch a K-beauty line.” Useful if you want a moisturizer; useless if you want equity.

This is the piece almost nobody writes: a map of the actual Korea-listed equities — with tickers, valuations, and an honest read on governance and risk. Most of these names have no US ADR, so foreign investors buy them in won (more on that below). If you are new to that mechanic, start with our guide on how to buy Korean stocks as a foreign investor.

📈 Why K-Beauty Is a Structural Export Story, Not a Fad

K-beauty is not a viral moment — it is a durable, decade-long export engine that just set an all-time record. In 2025, Korea’s cosmetics exports reached $11.4 billion, up 11.8% year-on-year, moving the country past the United States ($10.8bn) into the world’s No.2 exporter spot, behind only France ($24.3bn). The cosmetics trade surplus cleared $10 billion for the first time (Source: Korea’s Ministry of Food and Drug Safety (MFDS), press release of May 22, 2026).

Three facts inside that number matter more than the headline for an investor:

• Skincare, not makeup, is the moat. Skincare made up $8.53 billion — 74.7% of exports; color cosmetics were just 13.2%. K-beauty’s edge is formulation (essences, serums, sunscreens), which is stickier and higher-margin than trend-driven color.
• The US overtook China as the No.1 market. The United States bought $2.2 billion (+15% YoY), edging out China at $2.0 billion for the first time — and Chinese demand fell ~19% YoY (Source: MFDS, May 2026). The growth is diversifying away from the volatile China channel, not toward it.
• Reach is widening. Korea exported to 202 countries in 2025, up from 172 the year before. That breadth is what turns a “trend” into a structural category.

👑 The Regime Shift: How APR Dethroned Amorepacific

In 2025 the K-beauty leadership flipped: APR — a beauty-tech company built on home skincare devices — passed both LG H&H and Amorepacific to become Korea’s most valuable beauty company. The sequence is worth remembering because it is the clearest signal of what the market now rewards:

• June 2025: APR’s market cap overtook LG Household & Health Care.
• August 2025: APR passed Amorepacific, crossing ₩8 trillion.
• 2026: APR briefly became Asia’s most valuable beauty firm (peaking near ₩16tn), ahead of regional rivals including Japan’s Shiseido and China’s Proya.

As of the July 28, 2026 close, APR carries a ₩12.49 trillion ($8.4B) market cap versus Amorepacific’s ₩6.95 trillion ($4.7B) — roughly 1.8× the incumbent (Source: KRX listed shares × closing price; earnings from DART). The “why” is in the income statement: APR grew FY2025 revenue +111% to ₩1.53tn with a 23.9% operating margin, while Amorepacific — a far larger ₩4.25tn revenue base — earns a 7.9% operating margin and saw net income fall 58.9% (Source: DART FY2025 consolidated).

That net-income drop needs one line of context, because it is the most misread number in the sector. Amorepacific’s FY2024 net income was ₩601.6bn while its FY2024 operating income was only ₩220.5bn — the gap came from ₩424.1bn of other non-operating income booked in Q2 2024, when Amorepacific lifted its COSRX stake past control and re-measured the 38.4% it already owned (Source: DART H1 2024 consolidated statements). Strip that base effect out and Amorepacific’s operating income actually rose 52.3% in FY2025. We unpack that in our Amorepacific valuation deep dive.

The market is paying up for growth and margin, not heritage. That is the lens to carry into the stock-by-stock map below. For the deep dive on the new No.1, see our APR valuation breakdown.

💄 K-Beauty Stocks by Role: the Value-Chain Map

The single most useful way to think about K-beauty equities is by role in the value chain, not by size. There are three:

• Brands — own the label and the customer (Amorepacific, LG H&H, APR, d’Alba). High margin, high marketing risk.
• ODM “arms dealers” — the contract manufacturers who design and make the product for everyone else (Cosmax, Kolmar Korea). They win whichever brand wins.
• Beauty-tech / devices — home skincare hardware (APR’s Medicube AGE-R line), a higher-multiple, tech-adjacent niche.

All price and valuation figures are as of the July 28, 2026 KRX close. Market caps = KRX listed common shares × closing price. P/E = market cap ÷ FY2025 controlling-interest net income (the profit attributable to the parent’s own shareholders, ifrs-full_ProfitLossAttributableToOwnersOfParent) from DART consolidated filings — one basis for all six rows. Screeners that divide by consolidated net income will show lower multiples where a company has large minority interests: Cosmax reads 16.0× on that basis instead of 17.0× (₩123.1bn attributable vs ₩131.1bn consolidated), and Kolmar reads just 13.9× instead of 18.7×, because ₩43.1bn of its ₩168.2bn consolidated profit belongs to minority holders of subsidiaries it does not fully own (₩125.1bn attributable). Amorepacific’s 29.5× is against ₩235.7bn attributable, not the ₩247.3bn consolidated headline (28.1× on that basis). APR and d’Alba have no minority interests, so both bases give the same number. FY2025 revenue & YoY from the same DART filings. China-exposure ratings are qualitative; APR’s 80% overseas revenue share is FY2025 per company results (Feb 2026). All six trade on the KOSPI in Korean won.

⛏️ Brands vs. the “Arms Dealers”: Which Part of the Chain Should You Own?

If you believe in the category but can’t pick the winning brand, the ODM manufacturers — Cosmax and Kolmar Korea — are the classic pick-and-shovel play: they sell to everyone. They are the world’s two largest cosmetics ODMs (original design manufacturers) and Korea’s No.1 and No.2 by cosmetics production value — ₩1.61tn and ₩1.30tn in 2025 respectively, well clear of third-place Cosmecca at ₩353bn (Source: MFDS 2025 production statistics). The current boom is being driven less by the big houses than by a wave of small indie brands — the labels selling on Amazon and Olive Young that don’t own factories and outsource production to exactly these two.

The math shows up in Cosmax’s Q1 2026: consolidated revenue of ₩682 billion, with US sales up 46%, China up 20% and Korea up 17% year-on-year (Source: company/KED, Q1 2026). It runs plants in six countries — Korea, the US, China, Indonesia, Thailand and Japan — so a US brand ordering “made in USA” product still routes through Cosmax.

The trade-off is valuation versus visibility:

• Brands (APR, d’Alba) carry the upside if they become the next global name — and the marketing risk if a trend cools. They trade at 40×+ earnings.
• ODMs (Cosmax 17×, Kolmar 19×) are brand-agnostic and cheaper, but their margins are thinner — Cosmax 8.2% and Kolmar 8.8% operating margin in FY2025 versus APR’s 23.9% (Source: DART FY2025 consolidated) — and they are more exposed to raw-material and capacity cycles.

Neither is “right” — but confusing the two is the most common mistake foreign investors make in this sector. Owning APR and Cosmax are two completely different bets on the same tailwind.

💵 How Do Foreigners Actually Buy Korean Beauty Stocks?

You buy them in Korean won on the KRX through a broker with Korea market access — there are no US-listed ADRs for these names. Unlike Samsung or SK Hynix, none of the six beauty stocks here trades on the NYSE or Nasdaq, and none has a liquid ADR. That is the single biggest practical hurdle for a US or European investor.

Three routes, in order of directness:

• Direct KRW purchase — an international broker (Interactive Brokers and others) that offers KRX access lets you buy 090430, 278470, etc. directly. Our how-to-buy guide walks through the account and FX mechanics.
• Understand the pricing in dollars — because there’s no ADR, you’re always converting won to dollars in your head. Our explainer on Korean stock prices in USD covers the conversion and the FX drag on returns.
• Broad ETFs (indirect) — a Korea equity ETF gives you a sliver of Amorepacific/LG H&H, but the beauty weighting is tiny and you won’t get APR-style exposure. It’s a proxy, not a solution.

Currency is not a footnote here: with USD/KRW near 1,478 (as of Jul 28, 2026; daily official rates: Bank of Korea), a strengthening won adds to your dollar returns and a weakening won subtracts from them — independent of how the stock does.

🏛️ Governance & Shareholder Returns: the Value-Up Angle

K-beauty is a live test of Korea’s Value-Up reform: the newer companies are courting foreign shareholders aggressively, while the legacy houses sit inside classic chaebol/holding-company structures that carry the usual Korea Discount baggage. This split is where the language-arbitrage edge lives — the ownership filings rarely make it into English coverage.

• Amorepacific (090430) is the operating company under a holding-company structure. Amorepacific Holdings (002790) owns 22,250,869 common shares — 38.04%, and together with 19 related parties the controlling bloc holds 50.13% of the common stock (Source: DART 5% ownership filing, Jul 15, 2026; DART FY2025 annual report). Chairman Suh Kyung-bae also holds 10.65% of 090430 directly. Dividend is modest (₩1,240/share, ~1.0% yield at the Jul 28 close; Source: DART FY2025 dividend filing). That is outright majority control by the founding family — the exact profile the Value-Up program is trying to reform, and we break it down in our Amorepacific stock deep dive.
• LG H&H (051900) sits inside the LG Group under LG Corp, Korea’s model holding company. Its ₩2,000 dividend yields just 0.8% (Source: DART FY2025 dividend filing; yield at the Jul 28, 2026 close), and with a FY2025 net loss the payout is under pressure.
• Cosmax (192820) and Kolmar Korea (161890) are each founder-controlled through their own holding companies. Both pay small dividends (Cosmax ₩3,300 = 1.8%; Kolmar ₩864 = 0.9% yield — Source: DART FY2025 dividend filings, yields at the Jul 28, 2026 close) — respectable for growth-stage manufacturers, but not yet Value-Up stories. See our Cosmax deep dive and Kolmar Korea deep dive.
• d’Alba Global (483650) is the standout on shareholder returns: it launched Korea’s first shareholder-only store and targets a 25%+ payout ratio with a ₩20bn buyback (Source: d’Alba Global Corporate Value-Up disclosure via DART, 2026) — a genuine Value-Up posture from a 2025 IPO. We break the structure down in our d’Alba Global deep dive.

If you’re weighing these names on governance, read them through the framework in our guides to Korea’s Value-Up program and the Korea Discount. The short version: d’Alba is playing the new game; Amorepacific and LG H&H still carry the old structure.

📚 Lingo Check

🎯 Why It Matters for K-Export Stars

K-beauty is a textbook K-Export Star: a globally competitive Korean industry that sells the world something it wants, growing ~10% a year and now the world’s No.2 by export value. But the headline “$11.4 billion record” tells you nothing about which stock to own — and the English-language coverage stops at the products. Our job is to decode the equity: read the DART filings, map the value chain, and flag the governance and China risks Western analysts rarely check. The regime shift from Amorepacific to APR is exactly the kind of structural re-rating this site exists to catch early.

Disclaimer: This article is for informational and educational purposes only and is not investment advice, a recommendation, or a solicitation to buy or sell any security. Figures are sourced from DART, KRX, MFDS and Korea Customs as of the dates noted and may change. Prices and valuations are point-in-time and go stale quickly — always verify a live quote. Do your own research and consult a licensed financial adviser before investing.